Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

BACKGROUND: Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β(3)-adrenergic receptor agonist for the treatment of OAB—significantly improved daily number of urge...

Descripción completa

Detalles Bibliográficos
Autores principales: Staskin, David, Frankel, Jeffrey, Varano, Susann, Kennelly, Michael, Newman, Diane K., Rosenberg, Matt T., Shortino, Denise D., Jankowich, Rachael A., Mudd Jr, Paul N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159226/
https://www.ncbi.nlm.nih.gov/pubmed/35685566
http://dx.doi.org/10.1155/2022/6475014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159226/
https://www.ncbi.nlm.nih.gov/pubmed/35685566
http://dx.doi.org/10.1155/2022/6475014

Ejemplares similares